For the last quarter of 2017, are there any additional drugs with pass-through status?
Effective October 1, 2017, the Centers for Medicare & Medicaid Services (CMS) granted outpatient prospective payment system pass-through status to the four drugs below:
|C9491||Injection, avelumab, 10 mg|
|C9492||Injection, durvalumab, 10 mg|
|C9493||Injection, edaravone, 1 mg|
|C9494||Injection, ocrelizumab, 1 mg|